Literature DB >> 36118409

Salvage Strategies for Management of Testicular Tumors.

Smaranjit Chatterjee1, Sudhir Kumar Rawal1.   

Abstract

Testicular germ cell tumors (GCTs) comprise 2% of all human male malignancies and are the most common solid tumors in men between ages 15 and 35 years. Risk of contralateral testicular GCT is between 1 and 5%. Partial orchidectomy (PO) was originally described in 1984 by Richie. The evolving indications include metachronous tumors and tumor in solitary testicles. Also, small non-palpable lesions detected only by ultrasonography (USG) in asymptomatic patients is another indication. Salvagability is only chosen for tumors less than 2 cm in size. The key feature of PO is an inguinal approach with early vascular control using a rubber tourniquet before testicular mobilization into the field to avoid systemic tumor seeding. After, mass excision with a margin mandatory frozen section is done to assess adequacy of resection. Intra-op USG may be beneficial in small non-palpable lesions. Post op tumor markers are assessed and patients are taught self-examination of testis. Recent series shows that PO is safe and gives adequate oncological control. Carcinoma in situ (CIS) in the affected testis at PO or after testicular sparing surgery remains a challenge. At most centers, 20 Gy is recommended when adjuvant local radiation treatment is chosen to treat CIS. But this dose may hamper Androgen production. Radical orchiectomy remains the gold standard and should be discussed as part of informed consent. It is mandatory to highlight the risks of local recurrence and CIS, and treatment (observation, radiation, or completion orchiectomy) as well as the need for androgen supplementation and fertility risks before choosing testicular salvage procedures. © Indian Association of Surgical Oncology 2016.

Entities:  

Keywords:  Cisplatin; Testicular cancer; Testicular tumors

Year:  2017        PMID: 36118409      PMCID: PMC9478072          DOI: 10.1007/s13193-016-0614-1

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  24 in total

1.  Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants.

Authors:  P R Henon; H Liang; G Beck-Wirth; J C Eisenmann; M Lepers; E Wunder; G Kandel
Journal:  Bone Marrow Transplant       Date:  1992-04       Impact factor: 5.483

2.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.

Authors:  C R Nichols; S D Williams; P J Loehrer; F A Greco; E D Crawford; J Weetlaufer; M E Miller; A Bartolucci; L Schacter; L H Einhorn
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

3.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

Authors:  C R Nichols; P J Catalano; E D Crawford; N J Vogelzang; L H Einhorn; P J Loehrer
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

Review 4.  Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis.

Authors:  Merel R van Dijk; Ewout W Steyerberg; J Dik F Habbema
Journal:  Eur J Cancer       Date:  2006-03-30       Impact factor: 9.162

5.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Authors:  Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

6.  Preservation of antegrade ejaculation in retroperitoneal lymphadenectomy due to residual masses after primary chemotherapy for testicular carcinoma.

Authors:  E Solsona; I Iborra; J V Ricós; J L Monrós; R Dumont; J Casanova; V Guillem
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

7.  Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.

Authors:  Brett S Carver; Bobby Shayegan; Scott Eggener; Jason Stasi; Robert J Motzer; George J Bosl; Joel Sheinfeld
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

8.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.

Authors:  Maria De Santis; Alexander Becherer; Carsten Bokemeyer; Franz Stoiber; Karin Oechsle; Franz Sellner; Alois Lang; Kurt Kletter; Bernhard M Dohmen; Christian Dittrich; Jörg Pont
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

9.  Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.

Authors:  F Farhat; S Culine; C Théodore; M Békradda; M J Terrier-Lacombe; J P Droz
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

10.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.